Abstract
Importance Breath analysis has been explored as a non-invasive means to detect COVID-19. However, the impact of the emerging variants such as Omicron on the exhaled breath profile and hence the accuracy of breath analysis is unknown.
Objective To evaluate the diagnostic accuracies of breath analysis on detecting COVID-19 patients in periods where Delta and Omicron were most prevalent.
Design, Setting, and Participants A convenience cohort of patients testing positive and negative for COVID-19 using reverse transcriptase polymerase chain reaction (RT-PCR) were studied and included 167 COVID and non-COVID patients recruited between April 2021 and May 2022, which covers the period when Delta (and other variants prior to Delta) was the dominant variant (April – December 2021) and when Omicron was the dominant variant (January – May 2022). The breath from those patients were collected and analyzed for volatile organic compounds (VOCs) with a newly developed portable gas chromatography-based breath analyzer. Diagnostic patterns and algorithms were developed.
Results A total of 205 breath samples were analyzed from 167 COVID and non-COVID patients. The RT-PCR was conducted within 18 hours of the breath analysis to confirm the COVID status of the patients. Among 94 COVID positive samples, 41 samples were collected from the patients in 2021 who were assumed to be infected by the Delta variant (or other variants occurring in 2021) and 53 samples from the patients in 2022 who were assumed to be infected by the Omicron variant (BA.1 and BA.2). Breath analysis using a set of 4 VOC biomarkers was able to distinguish between COVID (Delta and other variants in 2021) and non-COVID with an overall accuracy of 94.7%. However, the accuracy dropped significantly to 82.1% when the same set of biomarkers were applied to the Omicron variant with and 21 out of 53 COVID positive being misidentified. A new set of 4 VOC biomarkers were found to distinguish the Omicron variant and non-COVID, which yielded an overall accuracy of 90.9%. Breath analysis was also found to be able to distinguish between COVID (for all the variants occurring between April 2021 and May 2022) and non-COVID with an overall accuracy of 90.2%, and between the Omicron variant and the earlier variants (Delta and other variants occurring in 2021) with an overall accuracy of 91.5%.
Conclusions and Relevance Breath analysis of VOCs using point of care gas chromatography may be a promising diagnostic modality for detection of COVID and similar diseases that result in VOC production. However, similar to other diagnostic modalities such as rapid antigen testing, challenges are posed by the dynamic emergence of viral variants. The results of this study warrant additional investment and evaluation on how to overcome these challenges and to exploit breath analysis to improve the diagnosis and care of patients.
Question Can volatile organic compounds (VOCs) in exhaled breath provide diagnostic information on COVID-19? Will variants such as Omicron B.1.1.529 and others affect the accuracy in breath analysis?
Findings A set of 4 VOC biomarkers were found to distinguish between Delta (and the variants occurring in 2021) from non-COVID. The Omicron variant (occurring in 2022) significantly affects VOC profiles requiring the search for a new set of VOC biomarkers to distinguish between Omicron and non-COVID.
Meanin These findings demonstrate the ability of breath analysis to distinguish between COVID and non-COVID, but also reveal the significant difference in the exhaled breath profile between COVID-19 patients during the period when Delta was most prevalent and when Omicron was most prevalent.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
National Institutes of Health via U18TR003812 and the Office of the Director of National Intelligence (ODNI), Intelligence Advanced Research Projects Activity (IARPA), via IARPA FA8650-19-C-9101
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
the University of Michigan Medical School Institutional Review Board HUM00103401 and HUM00210064 Approved
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
